Acute Myeloid Leukemia, in Relapse Clinical Trial
Official title:
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the samples will be taken during routinary clinical practice. The aim of this study is to analyze the immunobiology of Acute Myeloid Leukemia (AML) relapses after allogeneic HSCT for the generation of guidelines and personalized therapeutic pathways.
Background: The identification of leukemic relapses characterized by the "Human Leukocyte Antigens loss" event or by changes in the expression levels of genes involved in antigen presentation and lymphocyte co-stimulation demonstrate how a complete characterization of disease recurrence is necessary to ensure the patient a treatment that is as personalized and targeted as possible, avoiding the choice of sub-optimal or, sometimes, harmful therapies. Unfortunately, the identification of the post-transplant relapse mechanism is now far from being part of an established clinical routine, mainly due to the lack of quick and easy-to-access diagnostic tools and multicentre studies demonstrating the efficacy of a type of personalized therapeutic approach. The main objective of the study is to favor, exploiting the consolidated collaboration between the Italian transplant centers belonging to the Italian Group of Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapies (GITMO), the implementation in clinical practice of an in-depth biological study of relapses of leukemia in order to allow an increasingly targeted and effective planning of the therapeutic strategies to be implemented, ensuring better patient survival. The study is divided into two parts: - data collection, from clinical standard practice, of patients with relapse of the disease which will allow to standardize the therapeutic management process and will allow us to promote innovative clinical studies on acute myeloid leukemia post allogeneic HSCT, with the ultimate aim of improving the survival of these patients; - biological substudy that will allow to define the role of the tumor microenvironment in promoting or counteracting the phenomenon of relapse by identifying its specific alterations in the various forms of disease relapse. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02204085 -
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT06125652 -
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05105152 -
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
|
Phase 1 | |
Recruiting |
NCT05597306 -
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT04898894 -
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05546580 -
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
|
Phase 1 | |
Recruiting |
NCT03957915 -
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
|
Early Phase 1 | |
Recruiting |
NCT05317403 -
Venetoclax to Augment Epigenetic Modification and Chemotherapy
|
Phase 1 | |
Recruiting |
NCT04867928 -
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT04402541 -
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Not yet recruiting |
NCT04716452 -
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05211570 -
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT03690154 -
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
|
Phase 1 | |
Not yet recruiting |
NCT05854966 -
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Not yet recruiting |
NCT06459024 -
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
|
||
Recruiting |
NCT05735184 -
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
|
Phase 1 | |
Recruiting |
NCT05506332 -
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05949125 -
Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123
|
Phase 1 | |
Recruiting |
NCT06128044 -
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Completed |
NCT04321161 -
Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment
|
Early Phase 1 |